NCT03512236View on ClinicalTrials.gov

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

BC Pram Ins

Injection of BC Pram Ins

DRUG

Symlin® and Humulin®

Injection of pramlintide and human insulin

DRUG

Humalog®

Injection of lispro

DRUG

Placebo

Injection of 0.9% NaCl

Trial Locations (1)

Unknown

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
lead

Adocia

INDUSTRY

NCT03512236 - A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter